Last updated: November 27, 2023
Sponsor: Valerie Taylor
Overall Status: Active - Recruiting
Phase
2
Condition
Obsessive-compulsive Disorder
Mood Disorders
Anxiety Disorders
Treatment
FMT Capsule + SIMBA Capsule
Clinical Study ID
NCT05720793
NIM-FMT/OCD-2022
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adults who have a primary diagnosis of OCD
- on a stable appropriate dose of (SSRI) treatment for at least 12 weeks prior toBaseline
- insufficient response to current SSRI treatment indicated by persistence of symptoms.
Exclusion
Exclusion Criteria:
- Participant meets Diagnostic criteria for substance use, eating disorder,schizophrenia, or schizoaffective disorder
- Suicidality
- regular intake of antibiotics, prebiotics, or probiotics
- Clinically diagnosed with IBD, Crohn's disease, Ulcerative colitis, or Celiac disease
- Immune suppression
- intestinal obstruction
- Oropharyngeal dysphagia or other swallowing disorder
- < 2 bowel movements per week
- Breastfeeding, pregnant or seeking to get pregnant during the course of this study
Study Design
Total Participants: 20
Treatment Group(s): 1
Primary Treatment: FMT Capsule + SIMBA Capsule
Phase: 2
Study Start date:
June 01, 2023
Estimated Completion Date:
August 30, 2024
Connect with a study center
University of Calgary, TRW building
Calgary, Alberta T2N 4Z6
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.